Vardigan JD - Search Results

1

Na_v1.7 target modulation and efficacy can be measured in nonhuman primate assays.

Kraus RL, Zhao F, Pall PS, Zhou D, Vardigan JD, Danziger A, Li Y, Daley C, Ballard JE, Clements MK, Klein RM, Holahan MA, Greshock TJ, Kim RM, Layton ME, Burgey CS, Serra J, Henze DA, Houghton AK. Kraus RL, et al. Among authors: vardigan jd. Sci Transl Med. 2021 May 19;13(594):eaay1050. doi: 10.1126/scitranslmed.aay1050. Sci Transl Med. 2021. PMID: 34011626

2

Pharmacological validation of a novel nonhuman primate measure of thermal responsivity with utility for predicting analgesic effects.

Vardigan JD, Houghton AK, Lange HS, Adarayan ED, Pall PS, Ballard JE, Henze DA, Uslaner JM. Vardigan JD, et al. J Pain Res. 2018 Apr 11;11:735-741. doi: 10.2147/JPR.S152879. eCollection 2018. J Pain Res. 2018. PMID: 29692626 Free PMC article.

3

Pharmacological Characterization of the Novel and Selective α7 Nicotinic Acetylcholine Receptor-Positive Allosteric Modulator BNC375.

Wang X, Daley C, Gakhar V, Lange HS, Vardigan JD, Pearson M, Zhou X, Warren L, Miller CO, Belden M, Harvey AJ, Grishin AA, Coles CJ, O'Connor SM, Thomson F, Duffy JL, Bell IM, Uslaner JM. Wang X, et al. Among authors: vardigan jd. J Pharmacol Exp Ther. 2020 May;373(2):311-324. doi: 10.1124/jpet.119.263483. Epub 2020 Feb 24. J Pharmacol Exp Ther. 2020. PMID: 32094294

4

Application of Pharmacokinetic-Pharmacodynamic Modeling to Inform Translation of In Vitro NaV1.7 Inhibition to In Vivo Pharmacological Response in Non-human Primate.

Ballard JE, Pall P, Vardigan J, Zhao F, Holahan MA, Kraus R, Li Y, Henze D, Houghton A, Burgey CS, Gibson C. Ballard JE, et al. Pharm Res. 2020 Sep 4;37(10):181. doi: 10.1007/s11095-020-02914-9. Pharm Res. 2020. PMID: 32888082 Free PMC article.

5

Effects of a novel M4 muscarinic positive allosteric modulator on behavior and cognitive deficits relevant to Alzheimer's disease and schizophrenia in rhesus monkey.

Lange HS, Vardigan JD, Cannon CE, Puri V, Henze DA, Uslaner JM. Lange HS, et al. Among authors: vardigan jd. Neuropharmacology. 2021 Oct 1;197:108754. doi: 10.1016/j.neuropharm.2021.108754. Epub 2021 Aug 11. Neuropharmacology. 2021. PMID: 34389398

6

Translational Pharmacokinetic-Pharmacodynamic Modeling of NaV1.7 Inhibitor MK-2075 to Inform Human Efficacious Dose.

Ballard JE, Pall PS, Vardigan J, Zhao F, Holahan MA, Zhou X, Jochnowitz N, Kraus RL, Klein RM, Henze DA, Houghton AK, Burgey CS, Gibson C, Struyk A. Ballard JE, et al. Front Pharmacol. 2021 Dec 24;12:786078. doi: 10.3389/fphar.2021.786078. eCollection 2021. Front Pharmacol. 2021. PMID: 35002718 Free PMC article.

7

Improved cognition without adverse effects: novel M1 muscarinic potentiator compares favorably to donepezil and xanomeline in rhesus monkey.

Vardigan JD, Cannon CE, Puri V, Dancho M, Koser A, Wittmann M, Kuduk SD, Renger JJ, Uslaner JM. Vardigan JD, et al. Psychopharmacology (Berl). 2015 Jun;232(11):1859-66. doi: 10.1007/s00213-014-3813-x. Epub 2014 Dec 10. Psychopharmacology (Berl). 2015. PMID: 25491927

8

Behavioral and qEEG effects of the PDE10A inhibitor THPP-1 in a novel rhesus model of antipsychotic activity.

Vardigan JD, Lange HS, Tye SJ, Fox SV, Smith SM, Uslaner JM. Vardigan JD, et al. Psychopharmacology (Berl). 2016 Jul;233(13):2441-50. doi: 10.1007/s00213-016-4290-1. Epub 2016 Apr 27. Psychopharmacology (Berl). 2016. PMID: 27117142

9

The novel phosphodiesterase 10A inhibitor THPP-1 has antipsychotic-like effects in rat and improves cognition in rat and rhesus monkey.

Smith SM, Uslaner JM, Cox CD, Huszar SL, Cannon CE, Vardigan JD, Eddins D, Toolan DM, Kandebo M, Yao L, Raheem IT, Schreier JD, Breslin MJ, Coleman PJ, Renger JJ. Smith SM, et al. Among authors: vardigan jd. Neuropharmacology. 2013 Jan;64:215-23. doi: 10.1016/j.neuropharm.2012.06.013. Epub 2012 Jun 27. Neuropharmacology. 2013. PMID: 22750078

10

MK-801 produces a deficit in sucrose preference that is reversed by clozapine, D-serine, and the metabotropic glutamate 5 receptor positive allosteric modulator CDPPB: relevance to negative symptoms associated with schizophrenia?

Vardigan JD, Huszar SL, McNaughton CH, Hutson PH, Uslaner JM. Vardigan JD, et al. Pharmacol Biochem Behav. 2010 Apr;95(2):223-9. doi: 10.1016/j.pbb.2010.01.010. Epub 2010 Feb 1. Pharmacol Biochem Behav. 2010. PMID: 20122952

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

18 results

Search Page